Abstract

Purpose: Despite considerable efforts to improve treatment modalities for cholangiocarcinoma, a common form of malignant tumor, its long-term survival rate remains poor. Hydroxychloroquine (HCQ) is a 4-aminoquinoline derivative antimalarial drug that has antimalarial and autophagy inhibition effects and exhibits comprehensive therapeutic effects on various cancers. In this study, we aimed to explore the anticancer potential and the underlying molecular mechanism of HCQ in cholangiocarcinoma treatment in vitro and in vivo.Methods: Autophagy-related genes (ARGs) were obtained from the Human Autophagy Database and Molecular Signatures Database, and the expression profiles of ARGs were downloaded from the database of The Cancer Genome Atlas. Different expression gene sets were performed using R software. The Gene Ontology and KEGG enrichment analyses were performed to reveal significantly enriched signaling pathways and to identify differentially expressed genes in cholangiocarcinoma tissues. HuCCT-1 and CCLP-1 cells were exposed to different concentrations of HCQ. Cell proliferation was detected by Cell Counting Kit-8 (CCK-8), colony formation, and 5-ethynyl-2′-deoxyuridine (EdU) assays. Cell apoptosis and cycle arrest were detected by the Live/Dead cell assay and flow cytometry (FCM). The inhibition of autophagy was observed using fluorescence microscopy. The reactive oxygen species levels were assessed by fluorescence microscopy and flow cytometry. The protein levels were determined by western blot. A cholangiocarcinoma cell line xenograft model was used to evaluate the antitumor activity of HCQ in vivo.Results: Compared with normal tissues, there were 141 ARGs with an aberrant expression in cholangiocarcinoma tissues which were mainly enriched in autophagy-related processes. Inhibition of autophagy by HCQ effectively suppressed cholangiocarcinoma in vitro and in vivo. HCQ inhibited cell proliferation and induced apoptosis and cycle arrest in vitro by increasing ROS accumulation, which was involved in autophagy inhibition. The ROS scavenger reduced l-glutathione distinctly weakened HCQ-induced cell apoptosis and viability inhibition in cholangiocarcinoma cells. In addition, HCQ inhibited growth of cholangiocarcinoma cell line xenograft tumors.Conclusion: HCQ could inhibit cell proliferation and induce apoptosis in cholangiocarcinoma by triggering ROS accumulation via autophagy inhibition, which makes HCQ a potential antitumor drug candidate for cholangiocarcinoma treatment.

Highlights

  • Cholangiocarcinoma is a malignant carcinoma that originates from the bile duct epithelium, which is characterized by the hidden onset and atypical early symptoms (Bekaii-Saab et al, 2021)

  • MRNA expression profiles with 35 cholangiocarcinoma samples and 9 normal samples were collected from the The Cancer Genome Atlas (TCGA) database, and 232 autophagy-related genes (ARGs) were obtained from the Human Autophagy Database (HADB)

  • Gene Ontology (GO) functional enrichment analysis showed that differential expression of autophagy-related gene sets (DE-ARGs) were mostly enriched in autophagy and phagophore assembly sites to perform the functions of biological processes and cell components, respectively (Figures 1C,D)

Read more

Summary

Introduction

Cholangiocarcinoma is a malignant carcinoma that originates from the bile duct epithelium, which is characterized by the hidden onset and atypical early symptoms (Bekaii-Saab et al, 2021). Most patients are already in advanced stage when they are diagnosed for the first time, which leads to poor prognosis (O’Rourke et al, 2021). The main therapy for cholangiocarcinoma patients is surgical treatment (Rizvi et al, 2018). Only a small percentage of patients can undergo radical surgery, and the postoperative local recurrence and distant metastasis rates remain very high (Blechacz, 2017). New therapeutic methods such as targeted therapy and immunotherapy are gradually being developed to improve patients’ prognosis (Saeed et al, 2019). It is unfortunate that the treatment effect of cholangiocarcinoma remains unsatisfactory. It is imperative to identify new strategies for the treatment of patients with cholangiocarcinoma

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call